Synonyms: CEACIDE® | hMN14
Compound class:
Antibody
Comment: Labetuzumab is a humanised mouse monoclonal antibody targeting CEACAM5 (CD66e), a tumour marker that can be measured in serum.
Labetuzumab can be labelled with radioactive isotopes such as yttrium-90 and iodine-131, providing targeted radioimmumotherapy. Labetuzumab has been used to generate an antibody-drug conjugate (ADC) called labetuzumab govitecan, in which the antibody is covalently bound to SN-38, the active metabolite of the topoisomerase inhibitor, irinotecan. |
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
8127 | labetuzumab |
Synonyms |
CEACIDE® | hMN14 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 62 |
Other databases | |
GtoPdb PubChem SID | 249565931 |
Search PubMed clinical trials | labetuzumab |
Search PubMed titles | labetuzumab |
Search PubMed titles/abstracts | labetuzumab |
Wikipedia | Labetuzumab |